Artivion (NYSE:AORT) SVP Sells $44,933.71 in Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 1,259 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total value of $44,933.71. Following the completion of the sale, the senior vice president owned 41,921 shares in the company, valued at approximately $1,496,160.49. This represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Artivion Stock Performance

AORT traded up $0.31 on Wednesday, reaching $35.66. The stock had a trading volume of 300,261 shares, compared to its average volume of 399,410. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average price is $42.51 and its two-hundred day moving average price is $43.14. The company has a market cap of $1.71 billion, a P/E ratio of 178.32 and a beta of 1.59.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. Sell-side analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Needham & Company LLC reissued a “buy” rating and set a $58.00 target price on shares of Artivion in a report on Monday, February 2nd. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Citizens Jmp increased their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Finally, Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.97.

Institutional Trading of Artivion

Hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its position in shares of Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after acquiring an additional 20,010 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after buying an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after acquiring an additional 1,032 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in Artivion in the second quarter valued at $669,000. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Artivion by 364.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock worth $1,644,000 after purchasing an additional 41,487 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.